Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02785679
Other study ID # 011-16-MMC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 20, 2018
Est. completion date December 31, 2021

Study information

Verified date April 2021
Source Meir Medical Center
Contact Idit Lachover- Roth, MD
Phone 972-9-7472320
Email idit.roth@clalit.org.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Although other studies argue with this assumption and suggest early exposure to CMP might be protective against atopic dermatitis and CMP allergy. A cohort study that first introduction of CMP after 15-30 days of age, raised the risk for CMP allergy.The aim of this study is to investigate if early and continuous exposure to CMF will decrease CMP allergy rate.


Description:

Background: Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. The incidence of milk allergy is 1.5-3% in the first year of life, but only 60% of the reactions are IgE mediated. CMP allergy tends to resolve in approximately 45-50% of the infants at 1 year of age, in 60-75% at the age of 2, and 85-90% at 3 years. The range for IgE mediated CMP allergy is 29-76%. A recent study suggested that the natural history of CMP allergy might have changed over time, with slower rates of resolution and a higher proportion of children with disease persisting into adolescence and adulthood. In the past it has been described that there is more incidence of CMP allergy in children from families with positive history of allergy. Early feeding with CMP has been considered in the past as a risk factor for development of CMP allergy in high risk infants. Although other studies argue with this assumption and suggest early exposure to CMP might be protective against atopic dermatitis and CMP allergy. A cohort study that first introduction of CMP after 15-30 days of age, raised the risk for CMP allergy. A recent study on peanut allergy found that continuous early exposure to peanut dramatically decreased the incidence of peanut allergy. The research in the field of food allergy and especially in CMP allergy is very alert those days. But as far as the investigators knowledge, there are no prospective studies from the first days of life that examined the influence of early and continuous exposure to cow's milk formula (CMF) on CMP allergy. The existing data related to CMP allergy is controversial and inconclusive. Thus, no one can rely on it to establish clear recommendations for parents when is the best time to combine CMF in the infants diet. Working hypothesis and aims: The aim of the study is to investigate if early and continuous exposure to CMF will decrease CMP allergy rate. The investigators assumption is that the rate of CMP allergy in the intervention groups and in infants who are only feed by CMF, will be lower than in the group of infants who are exclusively breast feed. Methods: Recruitment of 2,500 infants from first day of life and divide the participants into 4 groups: 1. Exclusive breast feeding. 2. Exclusive CMF feeding. 3. Breast feeding with 20 cc of CMF per day. 4. Breast feeding with one meal per day of CMF. The mother will complete a survey questionnaire before the labor. Infants will be followed for 1 year. During this follow-up period -the participants will be examined by an allergologist at the age of 2 month and 1 year. In between, the infants will be followed by a phone questionnaire once in a month. Specific CM IgE analysis from umbilical cord blood and skin test at 2 month of age will be performed. Inclusion criteria - Term and near term newborns (gestational age of at least 36 weeks), normal birth weight, normal perinatal follow-up and without congenital defects. Expected results: The rate of CMP allergy in the intervention groups and in the group on exclusively CMF feeding will be lower than in the group on exclusive breast feeding. Importance: If the investigators will be able to prove the study hypothesis (and even if not), it will have a significant influence on the diet recommendations for infants. Probable implications to Medicine: If the investigators will get the expected results, the recommendations that exist today for infant's feeding can be changed.


Recruitment information / eligibility

Status Recruiting
Enrollment 2500
Est. completion date December 31, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 2 Days
Eligibility Inclusion Criteria: - Term and near term newborns (gestational age of at least 36 weeks) - normal birth weight - normal perinatal follow-up (physiological neonatal jaundice is not an exclusion criteria) - without congenital defects Exclusion Criteria: - Preterm newborns - Congenital defects - Newborn suffering from acute event

Study Design


Intervention

Dietary Supplement:
cow's milk formula
addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day

Locations

Country Name City State
Israel Meir medical center Kfar Saba

Sponsors (2)

Lead Sponsor Collaborator
Meir Medical Center Schneider Children's Hospital

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of cow's milk allergy in the intervention groups Measure the rate of cow's milk allergy infants in each group and compare the rate of allergy between the groups. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05943704 - The Frequency of Beef Allergy in Children With Cow Milk Allergy N/A
Completed NCT00874627 - Sublingual Milk Immunotherapy in Children N/A
Not yet recruiting NCT03664076 - COMISS Score for Detection of Cow's Milk Protein Allergy in Children With Recrrent or Persistent Gastrointestinal Manifistations in Infants Attending Assuit University Children Hospital - Egypt
Not yet recruiting NCT04576845 - The Effect of Early Childhood Cow's Milk Allergy Elimination Diet on Eating Behaviors, Nutrition, and Growth Status
Recruiting NCT05785299 - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy N/A
Not yet recruiting NCT04327297 - Mineral Status Ininfants With Cow's Milk Protein Allergy
Completed NCT02351531 - Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy Phase 3
Recruiting NCT05064917 - BAT Cow's Milk for the Replacement of the Food Challenge Test
Recruiting NCT05406141 - Nutrition Sufficiency, Allergy Efficacy and Safety of Neocate Jr in Children With Food Protein Allergy N/A
Recruiting NCT02087930 - Microbiota as Potential Target for Food Allergy
Completed NCT01940068 - A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates N/A
Completed NCT00664768 - A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy N/A
Recruiting NCT05618704 - Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula N/A
Not yet recruiting NCT03456479 - Diagnosis of Cow's Milk Protein Allergy Among Infants and Children in Assuit University Children Hospital N/A
Recruiting NCT03223181 - Assessment of Cow's Milk-related Symptom Scoring Awareness Tool in Young Turkish Children N/A
Completed NCT03236207 - Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula N/A
Active, not recruiting NCT03644381 - Milk Desensitization in Children N/A
Active, not recruiting NCT04249973 - Detection of Metabolite Biomarkers for the Early Diagnosis and Prognosis of Cow's Milk Allergy in Children
Not yet recruiting NCT04684329 - Serum Esnophilic Cationic Protein Level as Diagnostic Marker in Cow Milk Protein Allergy Infants
Completed NCT03004729 - Symptoms Based Awareness Confirmation Study - CoMiSS Validation N/A